NCT00834262View on ClinicalTrials.gov

Observational Study on Safety and Efficacy of Biphasic Insulin Aspart in Type 2 Diabetes Patients

CompletedOBSERVATIONAL
Enrollment

339

Participants

Timeline

Start Date

April 30, 2009

Primary Completion Date

February 28, 2010

Study Completion Date

February 28, 2010

Conditions
DiabetesDiabetes Mellitus, Type 2
Interventions
DRUG

biphasic insulin aspart 30

Dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation

DRUG

biphasic insulin aspart 50

Dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation

DRUG

biphasic insulin aspart 70

Dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation

Trial Locations (1)

44425

Novo Nordisk Investigational Site, Kfar Saba

Sponsors

Lead Sponsor

Novo Nordisk A/S
All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY